Hepatitis B Vaccine Policy Change Could Lead to Rise in Newborn Infections, Experts Warn

A significant shift in U.S. vaccine policy is raising concerns among public health experts, who predict a potential surge in Hepatitis B infections among newborns. Previously a universal recommendation for all infants, the Hepatitis B vaccine may now only be offered to newborns identified as high-risk. This move away from widespread vaccination, which has successfully kept infection rates low for over three decades, is alarming infectious disease specialists. They caution that this policy change could undermine years of progress in preventing Hepatitis B, potentially leading to a resurgence of the disease, endangering a new generation of children, and placing additional strain on the healthcare system. The established protocol has been a critical tool in public health, and its alteration prompts urgent discussion about the long-term implications for infant health and disease control.